Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

Background Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been previously described with a direct comparison with the assessments according to the...

Full description

Bibliographic Details
Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	F. Stephen Hodi, Pasi A. Janne, Mark M. Awad, Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, Anika E. Adeni, Hiroto Hatabu
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2016-12-01
Online Access:	https://jitc.bmj.com/content/4/1/84.full

Similar Items

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
by: F Stephen Hodi, et al.
Published: (2014-11-01)

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
by: Mariano Severgnini, et al.
Published: (2020-10-01)

Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome
by: Tetsuro Araki, et al.
Published: (2019-01-01)

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
by: Rawad Elias, et al.
Published: (2018-04-01)

Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer
by: Zhansheng JIANG, et al.
Published: (2017-02-01)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
by: Dylan J. Martini, et al.
Published: (2017-08-01)

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
by: Tong Wu, et al.
Published: (2023-08-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
by: Mark Awad, et al.
Published: (2020-10-01)

Assessment of pulmonary function in COPD patients using dynamic digital radiography: A novel approach utilizing lung signal intensity changes during forced breathing
by: Noriaki Wada, et al.
Published: (2024-12-01)

Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for  Non-small Cell Lung Cancer
by: Sixuan WU, et al.
Published: (2019-07-01)

Metabolism of tryptophan in non-small lung cancer patients with different effect of PD-1 / PD-L1 inhibitors immunotherapy
by: E. Yu. Zlatnik, et al.
Published: (2022-06-01)

CTLA-4 and PD-1/ PD-L1 immune checkpoint inhibitors in extensive stage small cell lung cancer
by: ZHENG Yang, et al.
Published: (2023-06-01)

Efficacy and safety of PD‐1/PD‐L1 inhibitors in elderly patients with advanced non‐small cell lung cancer
by: Li Li, et al.
Published: (2024-05-01)

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
by: Pengfei Cui, et al.
Published: (2020-05-01)

Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients
by: Linling Wang, et al.
Published: (2025-10-01)

Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment
by: Mizuki Nishino
Published: (2016-06-01)

The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer
by: Qian Zhu, et al.
Published: (2025-04-01)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
by: Yanping Li, et al.
Published: (2023-05-01)

Correction to: Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients
by: Lingling Wang, et al.
Published: (2026-06-01)

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
by: Xiaoyang Zhai, et al.
Published: (2020-09-01)

Grade 4 thrombocytopenia with PD-1 inhibitors following progression of PD-L1 inhibitor therapy in small cell lung cancer: a case report and literature review
by: An Wang, et al.
Published: (2025-12-01)

Impact of delayed addition of PD-1/PD-L1 inhibitors to chemotherapy on outcomes in patients with extensive-stage small cell lung cancer
by: Shuangqing Lu, et al.
Published: (2025-07-01)

Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer
by: Taichi Miyawaki, et al.
Published: (2023-01-01)

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
by: Naoya Nishioka, et al.
Published: (2022-05-01)

Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
by: Zi‐Chao Zhou, et al.
Published: (2022-08-01)

Anterior mediastinal masses in the Framingham Heart Study: Prevalence and CT image characteristics
by: Tetsuro Araki, et al.
Published: (2015-01-01)

Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer
by: Ning Li, et al.
Published: (2024-08-01)

In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
by: Linda Wanika, et al.
Published: (2024-03-01)

Efficacy and Safety of PD-1 Inhibitors Monotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer
by: SONG Pingan, CHEN Xiaoliang, YAO Yuan, GAO Jin, YANG Yang, CUI Hongchun, ZHANG Yi
Published: (2023-01-01)

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence
by: Seonggyu Byeon, et al.
Published: (2020-04-01)

Peripheral inflammatory factors as prognostic predictors for first-line PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer
by: Chen-xing Jin, et al.
Published: (2025-04-01)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
by: Ofek Mussafi, et al.
Published: (2022-08-01)

Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
by: Lian Yu, et al.
Published: (2023-03-01)

PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-analysis
by: Chao Song, et al.
Published: (2025-05-01)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
by: Si-Yang Liu, et al.
Published: (2017-07-01)

Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study
by: Toshihiko Doi, et al.
Published: (2024-08-01)

The clinical value of local consolidative therapy for oligo-residual disease in PD-1/PD-L1 inhibitors-treated non-small cell lung cancer
by: Yuqi Su, et al.
Published: (2024-12-01)

Perioperative PD-1/PD-L1 inhibitors for resectable non-small cell lung cancer: A meta-analysis based on randomized controlled trials.
by: Hai Huang, et al.
Published: (2024-01-01)

Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
by: Dimitrios Makrakis, et al.
Published: (2023-01-01)